Public Health First: Centre Blocks Sale and Distribution of 16 Irrational Drug Combinations

The Union Ministry of Health and Family Welfare has prohibited the manufacture, sale, and distribution of 16 Fixed Dose Combinations (FDCs) after a scientific review found that the medicines lacked adequate therapeutic justification and could pose potential risks to public health.

The ban, issued under Section 26A of the Drugs and Cosmetics Act, 1940 , has come into effect immediately. The move follows directions from the Supreme Court , which had called for a comprehensive assessment of FDCs available in the country to identify combinations that were irrational, ineffective, or unsafe.

The Drugs Technical Advisory Board (DTAB) had constituted an expert committee to examine the safety and efficacy of various FDCs. Based on the committee’s recommendations, the government decided to prohibit combinations where the possible health risks outweighed the intended therapeutic benefits .

Among the banned formulations are several antibiotic-based combinations , including Amoxicillin with Serratiopeptidase , Amoxicillin-Cloxacillin combinations , and Cefuroxime with Serratiopeptidase . Other prohibited medicines include certain painkiller, antispasmodic, diabetes-related, and dermatological preparations .

Health experts have raised concerns over irrational FDC use, including the risk of unnecessary exposure to multiple active ingredients, increased side effects, improper treatment outcomes, and antibiotic resistance in cases involving antimicrobial combinations.

The Ministry said the decision aims to ensure that only safe, effective, and scientifically validated medicines remain available to patients. Regulatory authorities, state drug controllers, and enforcement agencies have been directed to ensure strict implementation of the order.

The ban is expected to impact pharmaceutical companies manufacturing or marketing these combinations, requiring them to stop production, withdraw existing stocks, and comply with regulatory directions . Manufacturers, importers, and distributors have been advised to take immediate corrective measures.

The government said the action is part of its continuing efforts to promote rational medicine use and strengthen patient safety through evidence-based regulation of pharmaceutical products.